Compare H2O America (HTO) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Natera Inc. Common Stock — how do they compare? H2O America trades at $57.11 (market cap $2.40B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 23.8× H2O America's market cap, and H2O America pays a 3.07% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 39 Days and Natera Inc. Common Stock for 0 Days on average.
| HTO | NTRA | |
|---|---|---|
Market Cap | $2.40B | $57.03B |
Volume | 620,902 | 1,131,157 |
Sector | Utilities | Health |
52-Week High | $65.43 | $425.64 |
52-Week Low | $44.44 | $179.42 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $4.19B | $56.18B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.49, down 0.27% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with 12.91% net income margin and consistent earnings beats in recent quarters. Recent acquisitions in Texas expand operations but require significant capital investment. Cash flow trends improved from $10M in 2025 to $84M in 2026, supporting dividend sustainability.
Outlook remains positive with 83% analyst buy ratings and $66.50 consensus target offering 14% upside. Key risks include acquisition integration and execution challenges. The stock presents value for income investors given Dividend King status and strategic growth initiatives in regulated water utilities.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
